Karen Hamm Antman
Boston University · 184 works · 12,283 citations · h-index 56
Top works
- Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.
- Imatinib Mesylate — A New Oral Targeted Therapy
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression
- Kaposi's Sarcoma
- International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury
- An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
- Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
- A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
- Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
- Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
- Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
- Multimodality therapy for malignant mesothelioma based on a study of natural history
- Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups.
- Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
- Specific barriers to the conduct of randomized trials
- Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody
- Selection bias in clinical trials.
- Malignant Mesothelioma
- High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.